Dopamine D2 and D4 receptor ligands:: relation to antipsychotic action

被引:64
作者
Wilson, JM
Sanyal, S
Van Tol, HHM
机构
[1] Clarke Inst Psychiat, Lab Mol Neurobiol 3, Toronto, ON M5T 1R8, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
基金
英国医学研究理事会;
关键词
antipsychotic; clozapine; schizophrenia; dopamine D-4 receptor antagonist; neuroleptic loose; dopamine receptor; extrapyramidal symptom; dopamine D-2-like receptor;
D O I
10.1016/S0014-2999(98)00312-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since the discovery that the antipsychotic action of phenothiazines was mediated by dopamine D-2 receptors, the dopamine system has been scrutinized for schizophrenia related abnormalities. The focus has been to create neuroleptics with improved antipsychotic profiles and reduced side effects. With the identification of multiple dopamine receptor subtypes, the hypotheses regarding the role of dopamine in schizophrenia and antipsychotic action of neuroleptics have been refined. Even after the molecular identification of newer dopamine D-2-like receptor subtypes (D-3 and D-4), the dopamine D-2 receptor is still considered the predominant site for antipsychotic action. However, there has been much debate concerning the modulatory role of other dopamine receptor sites in the mechanism of action of antipsychotic drugs. Specifically, the dopamine D-4 receptor has received much attention in this regard, since the atypical antipsychotic agent, clozapine, preferentially blocks this receptor subtype as compared with dopamine D-2 and D-3 receptors. In this review we will highlight some of the observations and arguments regarding the involvement of the dopamine D-2 and D-4 receptor sites in the therapeutic efficacy of antipsychotic medication. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:273 / 286
页数:14
相关论文
共 123 条
  • [1] AMALRIC M, 1993, PROG BRAIN RES, V99, P209
  • [2] Cellular distribution of the rat D-4 dopamine receptor protein in the CNS using anti-receptor antisera
    Ariano, MA
    Wang, J
    Noblett, KL
    Larson, ER
    Sibley, DR
    [J]. BRAIN RESEARCH, 1997, 752 (1-2) : 26 - 34
  • [3] Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
    Arnt, J
    Skarsfeldt, T
    [J]. NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) : 63 - 101
  • [4] ASGHARI V, 1994, MOL PHARMACOL, V46, P364
  • [5] BALK JH, 1995, NATURE, V377, P424
  • [6] Distinct binding patterns of [H-3]raclopride and [H-3]spiperone at dopamine D-2 receptors in vivo in rat brain. Implications for PET studies.
    Bischoff, S
    Gunst, F
    [J]. JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1997, 17 (1-3): : 419 - 431
  • [7] DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA
    BRENNER, HD
    DENCKER, SJ
    GOLDSTEIN, MJ
    HUBBARD, JW
    KEEGAN, DL
    KRUGER, G
    KULHANEK, F
    LIBERMAN, RP
    MALM, U
    MIDHA, KK
    [J]. SCHIZOPHRENIA BULLETIN, 1990, 16 (04) : 551 - 561
  • [8] Bristow LJ, 1997, J PHARMACOL EXP THER, V283, P1256
  • [9] CLONING AND EXPRESSION OF A RAT D2 DOPAMINE RECEPTOR CDNA
    BUNZOW, JR
    VANTOL, HHM
    GRANDY, DK
    ALBERT, P
    SALON, J
    CHRISTIE, MJ
    MACHIDA, CA
    NEVE, KA
    CIVELLI, O
    [J]. NATURE, 1988, 336 (6201) : 783 - 787
  • [10] Radioreceptor binding profile of the atypical antipsychotic olanzapine
    Bymaster, FP
    Calligaro, DO
    Falcone, JF
    Marsh, RD
    Moore, NA
    Tye, NC
    Seeman, P
    Wong, DT
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 87 - 96